SCHEMBL15907310

SCHEMBL15907310

COc1cn2c(C#Cc3cc(C#N)cc(NC(=O)c4ccc(C(N)=O)cc4)c3)nnc2cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 6/20 0.40
PLAU P00749 1/20 0.37
ADORA2A P29274 1/20 0.36
SIRT2 Q8IXJ6 3/20 0.35
SIRT1 Q96EB6 3/20 0.35
SIRT3 Q9NTG7 3/20 0.35
NNMT P40261 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
MAPK14 Q16539 1/20 0.35
KIT P10721 1/20 0.34
DDR1 Q08345 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15907305 0.94 CSF1R (0.38) CSF1RPLAUADORA2ANNMTMKNK1
SCHEMBL15907306 0.87 KMT2A (0.41) CSF1RMEN1KMT2ACASP3SENP8
SCHEMBL18323184 0.80 GRM5 (0.33) CSF1RMEN1KMT2ACASP3SENP8
SCHEMBL15907313 0.79 KIT (0.44) KITDDR1
SCHEMBL18323212 0.79 KIT (0.51) KITDDR1
SCHEMBL15907314 0.78 CSF1R (0.32) CSF1R
SCHEMBL18323213 0.76 CSF1R (0.35) CSF1RNNMTMKNK1MKNK2
SCHEMBL18323200 0.75 CSF1R (0.36) CSF1RNNMTMKNK1MKNK2MEN1
SCHEMBL18323146 0.73 GRM5 (0.37) CSF1RKITDDR1
SCHEMBL18323185 0.71 GRM5 (0.41) CSF1RMEN1KMT2ACASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon ABL1, ABL2, MAP3K6 CSF1R 1848/4885PLAU 2198/4885ADORA2A 4600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.